Tolerance of BNT162b2 mRNA COVI-19 vaccine in patients with a medical history of COVID-19 disease: A case control study.
Vaccine
; 39(32): 4410-4413, 2021 07 22.
文章
在 英语
| MEDLINE | ID: covidwho-1284598
ABSTRACT
INTRODUCTION:
Studies evaluating BNT162b2 mRNA Covid-19 vaccine safety excluded subjects with a previous history of COVID-19 infection. The aim of our study was to focus on the tolerance of this vaccine this population.METHODS:
An anonymous self-reporting survey related to safety and tolerance of vaccine was completed by subjects 21 to 28 days after the first vaccine dose in two vaccination centers.RESULTS:
Subjects with prior COVID-19 disease history (n = 61) had higher systemic reactions than subjects without any previous history (n = 1987) (45.9% vs 29.7%, p = 0.01). Asthenia, headache and fever were significantly more frequent in COVID-19 + group than negative group (25.6% vs 15.2% p = 0.045, 19.7% vs 9.3% p = 0.01, 6.5% vs 0.9% p = 0.003 respectively). Grade of severity was higher in COVID-19 + than in COVID-19 - group (p = 0.03).CONCLUSION:
Our study confirms a higher risk of side effects in patients with preexisting SARS-CoV-2 disease but with a good overall tolerance.Keywords
全文:
可用
采集:
国际数据库
资料库:
MEDLINE
主要主题:
COVID-19
研究类型:
实验研究
/
观察性研究
/
预后研究
话题:
疫苗
限制:
人类
语言:
英语
期刊:
Vaccine
年:
2021
类型:
文章
相关文档
MEDLINE
...
LILACS
LIS